BioSpace News Archive

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic:.

HIGHLIGHTS Aroa lists on the ASX today after raising $45m at $0.75/share with an indicative market capitalisation of A$225m under the code ARX The Company has a range of five products that have been used in more than four million procedures to date, focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction Existing and new product pipeline focused on US$2.5b² total addressable market opportunity

Inozyme Pharma, Inc. (“Inozyme”) (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $112.0 million,

iTeos Therapeutics, Inc. announced the pricing of its initial public offering of 10,586,316 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by iTeos.